{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "asset_name": "zidesamtinib"
  },
  "asset": {
    "name": "zidesamtinib",
    "ticker": "NUVL",
    "company": "Nuvalent",
    "modality": "Small molecule kinase inhibitor",
    "stage": "NDA Filed",
    "one_liner": "Best-in-class ROS1 inhibitor with TRK-sparing selectivity for improved safety and broad mutation coverage",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "ROS1",
    "full_name": "ROS proto-oncogene 1, receptor tyrosine kinase",
    "class": "Receptor Tyrosine Kinase",
    "pathway": "ROS1 fusion → constitutive kinase activation → tumor growth",
    "biology": {
      "simple_explanation": "ROS1 is a receptor tyrosine kinase that when fused to various partner genes creates oncogenic fusion proteins driving tumor growth. ROS1 fusions occur in 1-3% of NSCLC patients, typically younger never-smokers.",
      "prevalence": "1-3% of NSCLC",
      "patient_demographics": "Often younger, never-smokers",
      "cns_involvement": "20-40% present with brain metastases; 30-55% develop brain mets at 1L progression"
    },
    "resistance_mutations": {
      "primary_mutation": "G2032R (observed in ~40% progressing on crizotinib)",
      "other_mutations": ["G1957A", "L1982V", "S1986F", "F2004C", "F2004V", "G2032K", "D2033N", "L2026M"]
    },
    "why_good_target": {
      "clinical_validation": "Multiple approved ROS1 TKIs (crizotinib, entrectinib, repotrectinib, taletrectinib) validate the target",
      "unmet_need": [
        "No approved therapy active after dual TRK/ROS1 inhibitors (repotrectinib, taletrectinib)",
        "Treatment-limiting CNS adverse events with current TRK/ROS1 inhibitors",
        "Limited durability - crizotinib mPFS only 19.3 months vs lorlatinib mPFS not reached in ALK"
      ]
    }
  },
  "indications": {
    "lead": {
      "name": "ROS1+ NSCLC (TKI pre-treated)",
      "stage": "NDA Filed",
      "rationale": "Patients progressing on prior ROS1 TKIs have limited options; zidesamtinib active against resistance mutations"
    },
    "expansion": [
      {
        "name": "ROS1+ NSCLC (TKI-naïve)",
        "stage": "Phase 2 ongoing",
        "rationale": "Potential for best-in-class 1L therapy based on early data"
      }
    ]
  },
  "clinical_data": {
    "trial_name": "ARROS-1 (NCT05118789)",
    "trial_design": {
      "phase": "Phase 1/2",
      "design": "Global open-label multi-cohort study",
      "enrollment": "539 patients enrolled (104 Phase 1 + 435 Phase 2)"
    },
    "populations": {
      "pivotal_safety": {
        "n": 432,
        "description": "ROS1+ NSCLC treated at RP2D as of March 21, 2025"
      },
      "tki_pretreated_efficacy": {
        "n": 117,
        "description": "Treated at RP2D by May 31, 2024 to allow ≥6 months DOR follow-up"
      },
      "tki_naive_preliminary": {
        "n": 35,
        "description": "TKI-naïve patients with preliminary data"
      }
    },
    "tki_pretreated_results": {
      "data_cutoff": "March 21, 2025",
      "orr_any_prior_tki": "44% (n=117)",
      "orr_1_prior_tki": "51% (n=65, crizotinib or entrectinib only)",
      "dor_1_prior_tki": "93% ≥18 months; median 22 months [17, NE]",
      "pfs_1_prior_tki": "23.8 months [23.8, NE]",
      "orr_g2032r_mutation": "54%",
      "dor_g2032r": "79% ≥6 months",
      "intracranial_orr_any_prior": "48%",
      "intracranial_orr_crizotinib_only": "85%"
    },
    "tki_naive_results": {
      "data_cutoff": "March 21, 2025 (preliminary)",
      "orr": "89% (n=35)",
      "dor": "96% ≥12 months",
      "intracranial_orr": "83%",
      "intracranial_cr": "67%"
    },
    "safety": {
      "discontinuation_rate": "2%",
      "dose_reduction_rate": "10%",
      "peripheral_edema": "29% (Gr3: 3%)",
      "key_differentiator": "TRK-sparing design avoids CNS toxicity seen with TRK inhibitors"
    }
  },
  "mechanism_differentiation": {
    "trk_sparing": {
      "selectivity_ros1_vs_trkb": "670x (vs competitors: 1.4x-7.7x)",
      "clinical_relevance": "Avoids dizziness, ataxia, cognitive effects associated with TRK inhibition"
    },
    "mutation_coverage": {
      "wild_type_ic50": "Sub-10 nM",
      "g2032r_ic50": "Sub-10 nM",
      "other_mutations": "Sub-10 nM across S1986F, F2004C/V, L2026M, D2033N"
    },
    "cns_penetration": {
      "kpuu": "~0.1 (similar to lorlatinib preclinically)",
      "clinical_evidence": "48-85% intracranial ORR depending on prior therapy"
    }
  },
  "catalysts": [
    {
      "event": "PDUFA target action date",
      "timing": "September 18, 2026",
      "importance": "critical",
      "what_to_watch": "FDA approval decision for ROS1+ NSCLC"
    },
    {
      "event": "TKI-naïve data maturation",
      "timing": "2026",
      "importance": "high",
      "what_to_watch": "Durability of 89% ORR in frontline setting"
    }
  ],
  "competitive_landscape": {
    "approved_ros1_tkis": [
      {
        "drug": "crizotinib",
        "company": "Pfizer",
        "limitation": "Limited mutation coverage, modest CNS activity"
      },
      {
        "drug": "entrectinib",
        "company": "Roche",
        "limitation": "TRK-related toxicity, limited post-crizotinib activity"
      },
      {
        "drug": "repotrectinib",
        "company": "BMS",
        "limitation": "TRK-related CNS toxicity (dizziness 58%, dysgeusia 50%)"
      },
      {
        "drug": "taletrectinib",
        "company": "Iota",
        "limitation": "TRK-related toxicity"
      }
    ],
    "zidesamtinib_advantages": [
      "670x ROS1 vs TRKB selectivity (vs 1.4-7.7x for competitors)",
      "Broad mutation coverage including G2032R",
      "Strong CNS activity (48-85% IC-ORR)",
      "Clean safety profile (2% discontinuation)"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "High - NDA filed based on strong pivotal data",
    "peak_sales_estimate": "$570M-$855M US; higher with global expansion",
    "key_risks": [
      "Competition from established TRK/ROS1 inhibitors",
      "Commercial execution as first launch",
      "Label breadth (TKI-naïve vs TKI-pretreated)"
    ]
  },
  "market_opportunity": {
    "us_ros1_patients": "3,000-4,500 annually",
    "global_ros1_patients": "10,000-15,000 annually",
    "us_peak_sales": "$570M-$855M",
    "pricing_assumption": "Similar to other targeted oncology TKIs"
  }
}
